Bravecto Plus contains fluralaner (280 mg/ml), an ectoparasiticide which provides systemic activity against ticks (lxodes ricinus) and fleas (Ctenocephalides felis), and moxidectin (14 mg/ml), an endoparasiticide which provides systemic activity against a range of internal worms, including heartworm (Dirofilaria immitis), intestinal roundworm and hookworm.
Bravecto Plus is applied topically using the "Twist'n'Use" pipette. Once applied, the product kills ticks and fleas for 12 weeks, while also treating intestinal roundworm and hookworm and preventing heartworm disease for eight weeks.
Bravecto Plus can also be used as part of a treatment strategy for flea allergy dermatitis.
Bravecto was first launched in 2014 as a chewable tablet for dogs. In 2016 Bravecto spot-on was launched as a topical solution for dogs and cats. More than 80 million doses of Bravecto have been sold in 72 countries since 2014.
Amanda Melvin, marketing manager, at MSD Animal Health, said: "We are pleased to introduce the latest innovation in feline parasite protection to the Bravecto family."
For more information, refer to the summary of product characteristics or contact your MSD account manager.
Veterinary Surgeon Jobs in England | Scotland | Wales | Ireland | Worldwide and
Veterinary Locums |
Follow VS Jobs on Facebook | Linkedin | Twitter | Contact
Click here to learn more about display and email advertising on VetSurgeon.org
Veterinary Forums | Veterinary News | Veterinary CPD | Veterinary Galleries
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary Medicine | Veterinary Neurology | Veterinary Oncology | Veterinary Surgery